Sugi Predict

Sugi Predict / Compounds / SCHEMBL17569708

SCHEMBL17569708

SCHEMBL17569708

c1cc(-c2nccc3[nH]c(-c4n[nH]c5ncc(-c6cncc(OCCN7CCCC7)c6)cc45)nc23)ccn1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DYRK1A Q13627 14/20 0.57
▸ CLK2 P49760 13/20 0.57
▸ WNT1 P04628 4/20 0.56
▸ CLK3 P49761 11/20 0.54
▸ GSK3B P49841 2/20 0.44
▸ GAK O14976 1/20 0.43
▸ DYRK3 O43781 1/20 0.43
▸ JAK2 O60674 1/20 0.43
▸ PRKD3 O94806 1/20 0.43
▸ MAP4K4 O95819 1/20 0.43
▸ NQO2 P16083 1/20 0.43
▸ CSNK2A2 P19784 1/20 0.43
▸ FECH P22830 1/20 0.43
▸ JAK1 P23458 1/20 0.43
▸ TYK2 P29597 1/20 0.43
▸ MAPK8 P45983 1/20 0.43
▸ MAPK9 P45984 1/20 0.43
▸ CSNK1A1 P48729 1/20 0.43
▸ CSNK1D P48730 1/20 0.43
▸ CSNK1E P49674 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17569658 0.93 WNT1 (0.61) DYRK1ACLK2WNT1CLK3GSK3B
SCHEMBL17569698 0.92 WNT1 (0.59) DYRK1ACLK2WNT1CLK3GSK3B
SCHEMBL17569840 0.92 WNT1 (0.53) DYRK1ACLK2WNT1CLK3GSK3B
SCHEMBL17570009 0.92 WNT1 (0.60) DYRK1ACLK2WNT1CLK3GSK3B
SCHEMBL17588510 0.91 DYRK1A (0.66) DYRK1ACLK2WNT1CLK3GSK3B
SCHEMBL17569832 0.91 DYRK1A (0.54) DYRK1ACLK2WNT1CLK3GSK3B
SCHEMBL17555894 0.91 WNT1 (0.67) DYRK1ACLK2WNT1CLK3GSK3B
SCHEMBL17570023 0.90 WNT1 (0.53) DYRK1ACLK2WNT1CLK3GSK3B
SCHEMBL17569842 0.90 WNT1 (0.54) DYRK1ACLK2WNT1CLK3GSK3B
SCHEMBL17569727 0.89 WNT1 (0.57) DYRK1ACLK2WNT1CLK3GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10206929-B2 3-(1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine and therapeutic uses thereof SAMUMED, LLC (US) 2019-02-19 — — US claimed
US-20180325910-A1 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF VICKERS-SPLICE CO-INVESTMENT LLC (KY) 2018-11-15 — — US claimed
US-9889140-B2 3-(1H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridine and therapeutic uses thereof SAMUMED, LLC (US) 2018-02-13 — — US claimed
US-20170224697-A1 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF VICKERS-SPLICE CO-INVESTMENT LLC (KY) 2017-08-10 — — US claimed
US-9493487-B2 3-(1H-imidazo[4,5-C]pyridin-2-YL)-1H-pyrazolo[3,4-B]pyridine and therapeutic uses thereof SAMUMED, LLC (US) 2016-11-15 — — US claimed
WO-2016040193-A1 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF SAMUMED, LLC (US) 2016-03-17 — — WO claimed
US-10206929-B2 3-(1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine and therapeutic uses thereof SAMUMED, LLC (US) 2019-02-19 — — US disclosed
US-9889140-B2 3-(1H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridine and therapeutic uses thereof SAMUMED, LLC (US) 2018-02-13 — — US disclosed
US-9889140-B2 3-(1H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridine and therapeutic uses thereof SAMUMED, LLC (US) 2018-02-13 — — US disclosed
US-20170224697-A1 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF VICKERS-SPLICE CO-INVESTMENT LLC (KY) 2017-08-10 — — US disclosed
US-20170224697-A1 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF VICKERS-SPLICE CO-INVESTMENT LLC (KY) 2017-08-10 — — US disclosed
US-9493487-B2 3-(1H-imidazo[4,5-C]pyridin-2-YL)-1H-pyrazolo[3,4-B]pyridine and therapeutic uses thereof SAMUMED, LLC (US) 2016-11-15 — — US disclosed
US-9493487-B2 3-(1H-imidazo[4,5-C]pyridin-2-YL)-1H-pyrazolo[3,4-B]pyridine and therapeutic uses thereof SAMUMED, LLC (US) 2016-11-15 — — US disclosed
US-20160068549-A1 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF MED-PATHWAYS II LIMITED (VG) 2016-03-10 — — US disclosed
US-20160068549-A1 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF MED-PATHWAYS II LIMITED (VG) 2016-03-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160068549-A1 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF WNT1, WNT3, WNT3A DYRK1A 949/4885CLK2 2369/4885WNT1 1/4885
US-20170224697-A1 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF WNT1, WNT3, WNT3A DYRK1A 949/4885CLK2 2369/4885WNT1 1/4885
US-20180325910-A1 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF WNT1, WNT3, WNT3A DYRK1A 949/4885CLK2 2369/4885WNT1 1/4885
US-10206929-B2 3-(1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine and therapeutic uses thereof WNT1, WNT3, WNT3A DYRK1A 949/4885CLK2 2369/4885WNT1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.